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Abstract 
Purpose of review: HIV-infected children are at increased risk of developing cancer. Many of the 
cancers in HIV-infected children are linked to immunosuppression and oncogenic co-infections. 
Worldwide most HIV-infected children live in sub-Saharan Africa, but cancer data for this population 
are scarce. In this article we review the current literature on the epidemiology and prevention of 
cancer in HIV-infected children. 
Recent findings: Combined antiretroviral therapy (cART) reduces the risk of developing cancer in HIV-
infected children. Cancer risk remains increased in children who start cART at older ages or more 
advanced immunosuppression as compared to children who start cART at younger age and with mild 
immunosuppression. Starting cART before severe immunosuppression develops is key to prevent 
cancer in HIV-infected children but most children in low-income countries start cART at severe 
immunosuppression levels. Vaccination against high risk variants of human papilloma virus may 
protect again HPV-associated cancer later in life.  However, tailoring of HPV-vaccination guidelines 
for HIV-infected children and young women awaits answers to determine the best vaccination 
strategies. 
Summary: Better data on the short and long-term risk of developing cancer and the effects of 
preventive measures in HIV-infected children from regions with high burden of HIV/AIDS are urgently 
needed. 
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Introduction 
HIV-infected children have an increased cancer risk due to a compromised immune system and an 
increased susceptibility to oncogenic viruses [1,2]. Worldwide 1.8 million children aged 0-14 years 
are HIV-infected and at increased risk of developing cancer. Most of these children live in Africa: 1.04 
million (58%) in Eastern and Southern Africa and 0.5 million (29%) in Western and Central Africa. In 
Asia-Pacific the total number of HIV-infected children is 193,000 (11% of HIV-infected children 
worldwide) and 32,200 (2%) in Latin America and the Caribbean’s (Figure 1). Cancer mortality in HIV-
infected children remains high in resource-limited countries. Median survival in HIV-infected children 
and adolescents with Kaposi sarcoma (KS) was less than six months in a recent trial from Malawi [3]. 
In Uganda, median survival in HIV-infected children with Burkitt lymphoma was 11.8 months [4]. In a 
study from South Africa 10% of all HIV-infected children with cancer died of treatment related 
complications and severe infections [5]. Reliable estimates on the burden of cancer and measures to 
prevent cancer in HIV-infected children are warranted, especially in resource-limited countries with 
large burdens of HIV/AIDS. There is a paucity of cancer incidence studies in HIV-infected children 
from Sub-Saharan-Africa, where the majority of HIV-infected children live [6]. In this article we 
review the current literature on the epidemiology and prevention of cancer in HIV-infected children. 
 
Methods 
We searched Medline for the period 08/2011-08/2016 using the following search terms: 
(((HIV[Title/Abstract] OR AIDS[Title/Abstract])) AND (cancer[Title/Abstract] OR 
neoplasm*[Title/Abstract] OR tumor*[Title/Abstract] OR tumour*[Title/Abstract])) AND (infant* OR 
children). Additional searches were done for specific topics of interest, such as African countries and 
prevention. We included articles that were published in the last five years and highlighted those of 
special interest from the last 18 months. Cancer treatment and outcome is not covered in this article.  
 
Epidemiology of cancer in HIV-infected children 
Producing reliable cancer incidence estimates in HIV-infected pediatric populations is a challenge: 
HIV-cohorts may not record cancer cases and cancer registries may not record HIV-infection status. 
Record linkages between data of HIV-treatment programs or HIV-registries and cancer registries have 
been identified as a potential solution to this problem [7,8]. Three recent studies from the USA, 
Taiwan and South Africa (SA) have used this method to estimate cancer incidence rates in HIV-
infected children [9–11]. The SA study linked data at five pediatric cART programs using probabilistic 
record linkage methods with four referral pediatric oncology units [9]. Amongst a total of 11,707 
children, 47 prevalent and 24 incident cancer cases were identified. The overall cancer incidence rate 
was 82/100,000 person-years. The most frequent cancers were KS and non-Hodgkin lymphoma (NHL) 
with incidence rates of 34 and 31/100,000 person-years, respectively. The incidence rate for all non 
AIDS-defining cancers (NADC) combined was 17/100,000 person-years. Risk factors identified were 
older age at starting cART (10 years versus <3 years, adjusted hazard ratio (HR) 7.3, 95%CI 2.2-24.6) 
and severe and advanced immunodeficiency as compared to mild or no immunodeficiency at 
enrolment into program (adjusted HR 3.5, 95%CI 1.1-12). The risk of developing cancer was reduced 
by 70% in children receiving combination antiretroviral therapy (cART) compared to children not 
receiving cART (adjusted HR 0.29, 95%CI 0.09-0.86). There were insufficient incident cancer cases to 
identify risk factors for specific cancers. This was one of the first studies to show a protective effect 
of cART on the risk of developing cancer at patient level in children. Although the study used data 
from referral pediatric oncology units to improve cancer ascertainment, under-ascertainment cannot 
be excluded given that children diagnosed with cancer may not reach specialized services. The study 
highlighted the need for early HIV diagnosis and cART initiation before advanced immunodeficiency 
develops to further reduce the burden of cancer in HIV-infected children. A recent multi-regional 
analysis has shown that many children in low-income countries start cART at severe 
immunosuppression levels (62% and 65% in girls and boys) compared to high income countries (21% 
and 28% in girls and boys) [12]. Reasons for the late start are manifold and several studies evaluated 
acceptance of HIV testing, linkage to care and cART initiation [13]. However, few reported long-term 
outcomes [14] and none provided cancer data. 
Simard et al. investigated the long-term cancer risks in young adults diagnosed with AIDS during 
childhood [10]. The study was based on the US HIV/AIDS Cancer Match Study using record linkage 
between HIV and cancer registries. Participants were followed up for up to 10 years. Compared to 
the general population children diagnosed with AIDS had an increased risk of developing KS, NHL and 
NADCs, with leiomyosarcoma being the most frequent NADC. Comparing cancer incidence in the pre-
cART with the cART era the risk of developing KS was reduced by almost 90% (relative risk (RR) 0.13, 
95%CI 0.20-0.74) and the NHL risk by 60% (RR 0.40, 95%CI 0.21-0.75). The risk of developing NADCs 
did not decrease with the advent of cART (RR 0.98, 95%CI 0.33-2.86). The study highlighted that the 
risk of developing certain cancers remains increased in persons diagnosed with AIDS during 
childhood and the need for continued cancer monitoring in this population even with the initiation of 
cART. With improved access to care in low- and middle-income countries there are now growing 
numbers of HIV-infected children who start cART earlier and who live into adolescence and 
adulthood. Studies looking at long-term cancer risk in persons with long-term exposure to HIV-
infection, immunosuppression and cART are urgently needed for African and other affected 
countries.  
Lastly, the study from Taiwan used record linkage methods to estimate cancer incidence in HIV-
infected children using the Nationwide Health Insurance database [11]. However, with 207 included 
children the study was rather small.  
Incidence rates for KS, NHL and NADC differ substantially between these three studies from different 
geographic areas (table 1). It is also difficult to compare these studies given the differences in study 
design, inclusion criteria and analysis methods. This problem was addressed in a recent multiregional 
cohort study that directly compared the risk of developing KS in children starting cART in different 
geographic regions. Of the 24,991 HIV-infected children from Eastern Africa, Southern Africa and 
Europe starting cART, 26 children developed incident KS [15]. The study showed that KS (caused by 
an infection with Human Herpes Virus 8 (HHV-8)), is a frequent cancer in sub-Saharan Africa (SSA) 
and in SSA migrants in Europe, but cases are rare in children outside of this regions. Incidence rates 
per 100,000 person-years were 86 in Eastern Africa, 11 in Southern Africa, and 81 in children of SSA 
origin living in Europe, but zero in Asia-Pacific and European children of non- SSA origin (Figure 2). 
Higher age at starting cART and advanced HIV/AIDS stage were risk factors for developing KS. 
Regional differences persisted after adjusting for potential confounders and may point to higher 
HHV-8 co-infection rates in HIV-infected children from SSA. However, data for HHV-8 seroprevalence 
were not available in that study. In conclusion, the study underscores the need to start cART early in 
HIV-infected children at high risk for KS before advanced immunosuppression develops.  
Early cART initiation may also help to reduce the risk of new HHV-8 infections in children living in 
endemic areas. Recent studies demonstrated that HIV-infected children have a higher risk of co-
infection with HHV-8 compared to HIV-uninfected children [16,17]. An observational study from 
Zambia suggested that in HIV-infected children receiving cART the risk of HHV-8 infection was similar 
to HIV-uninfected children [17]. In contrast, in HIV-infected children not receiving cART the risk of 
acquiring HHV-8 was six-times higher compared to HIV-uninfected children (incidence rate ratio 5.97, 
95%CI 3.13-11.41) [17]. 
 
Prevention of Cancer in HIV infected and exposed children 
In this section we review the latest World Health Organization (WHO) guidelines for the early testing 
and treatment of HIV-infected children and its implications, including cancer risks in HIV and 
antiretroviral drugs (ARV) exposed but uninfected children. Lastly we discuss vaccination against 
Human Papilloma Virus (HPV) in HIV-infected children to prevent cervical cancer later in life. 
 
Early testing and treatment 
In the WHO “Consolidated guidelines on HIV testing services” (2015), special mention is made of HIV-
testing for infants/children and adolescents [18]. Scaling up of Early Infant Diagnosis (EID) is thought 
to be improved by task-shifting to trained and supervised lay providers. The use of point-of-care HIV 
testing is carefully considered with rapid diagnostic tests for HIV-serology recommended to assess 
HIV-exposure in infants less than four months, to rule out HIV in asymptomatic HIV-exposed infants 
at nine months and to diagnose HIV in children older than 18 months. The development of point-of-
care virological assays could further improve EID access [18,19]. WHO suggests governments re-
consider the age of consent to allow greater autonomy for HIV-testing among adolescents. 
adolescents [18]. However, to optimally prevent malignancy and achieve mortality and morbidity 
benefits, HIV diagnosis needs to be linked to prompt cART initiation and long-term retention on 
treatment, which could prove challenging in resource-limited settings.  
Updated treatment recommendations support the initiation of cART for HIV-infected adolescents 
and children regardless of WHO clinical stage and CD4 cell count, particularly infants diagnosed 
within the first year of life. Priority is given to children two years and younger, children between two 
and five years with WHO clinical stage 3 or 4 or CD4 count ≤ 750cell/mm3 or CD4 percentage <25% 
and children older than five years (including adolescents) with WHO stage 3/4 or CD4 count ≤ 
350cell/mm3 [19]. 
The new guidelines however, introduce the concern of cumulative effects of ARV therapy on a 
growing child as a result of early cART initiation with life-long duration. Possible strategies to reduce 
overall lifetime exposure and mitigate cumulative side-effects could include early time-limited cART. 
The CHER study (Children with HIV Early Antiretroviral randomized trial) investigated the effects of 
early time-limited cART initiation compared to deferred cART in infants [20]. HIV-infected infants 6-
12 weeks of age with CD4 percentage >25% were randomized to deferred therapy (ART-Def), early 
cART restricted to 40 weeks (ART-40W) or early cART restricted to 96 weeks (ART-96W) with 3.5 
years follow-up. Hazard ratios for death for cART-40W and cART-96W were 0.40 (p = 0.02) and 0.45 
(p=0.36) respectively compared to cART-Def. Cumulative probability of clinical disease progression or 
death by 3.5 years was 41% in cART-Def, 28% in the cART-40W and 21% in the cART-96W groups. The 
CHER trial reported that primary clinical, immunological and virological endpoints for early-time 
limited cART were superior to deferred cART in asymptomatic HIV-infected infants. However, there 
was no comparison between time-limited and continuous early cART, follow-up was too short to fully 
assess the effects of the different strategies on incident malignancy and the strategy may not be 
feasible in lower-resource settings because of its complexity and the need for close clinical and CD4 
monitoring. Overall, the idea of time-limited cART in infants is appealing but data regarding its 
efficacy compared to continuous cART is lacking.  
 
Cancer risk in HIV and ARV exposed but uninfected children 
While ARV prophylaxis for the prevention of mother-to-child HIV transmission has been 
tremendously successful, new challenges regarding the health outcomes of HIV and ARV exposed, 
uninfected infants are anticipated. Amongst these is the risk of cancer amongst infants exposed to 
HIV and ARV perinatally. Few studies have comprehensively investigated this risk with most studies 
hampered by short-term follow-up periods [21–25]. In the most recent study with a 16-year follow-
up period in New Jersey, USA, cancer registry data was linked to HIV case surveillance data to 
determine the risk of cancer amongst HIV-exposed, uninfected infants perinatally exposed to ARV 
prophylaxis [26]. For 3,805 HIV-exposed uninfected children the incidence of all cancer types was 
13.7/100,000 person-years (95%CI 3.7-35.2). Cancer incidence was not significantly different 
between HIV-exposed children unexposed to ARV prophylaxis (22.5/100,000 person-years) and 
children exposed to ARV prophylaxis (14.3/100,000 person-years). Another study showed an 
increased risk of developing cancer in children exposed to didanosine in-utero as compared to the 
other ARVs [25]. The authors concluded that didanosine should be strictly contraindicated in 
pregnancy. Continued vigilance of the health effects of ARV prophylaxis in infants is required as the 
prevention of mother-to-child transmission program gains momentum and success globally in 
heterogeneous settings.  
 HPV-vaccination for the primary prevention of invasive cervical cancer 
HIV-infected individuals are at higher risk for all types of HPV-related cancer compared to the HIV-
uninfected individuals [27]. Bi-, quadri- and the newly introduced nanovalent HPV-vaccine offer 
effective protection against infection with high risk HPV variants and have acceptable safety profiles 
in the general population [28]. Vaccinations are recommended for girls and women aged 9 years up 
to 25 years old prior to HPV exposure [29]. There are few studies investigating the immunogenicity 
and safety of the HPV-vaccination in HIV-infected populations [30]. However, from the available 
evidence, both the bi- and quadrivalent HPV-vaccines have demonstrated high seroconversion rates 
and acceptable safety profiles in various HIV-infected populations (children, female adolescents and 
adults). The nanovalent vaccine, is still untested in the HIV-infected population [31]. Seroconversion 
rates for the quadrivalent vaccine of more than 92% were reported in HIV-infected boys and girls 
aged 7-12 years [32] and HIV-infected young women 16-23 years (ART and non-ART groups) [33]. 
However Levin et al reported lower antibody titres to HPV- 6 and 18 in HIV-infected children (7-12 
years) compared to historical controls [32]. Kahn et al also reported lower antibody titres in young 
HIV-infected women (16-23 years) not on cART [33], but similar antibody titres for women receiving 
cART compared to the HIV-uninfected comparison group [33]. 
In a study of the bivalent vaccine in HIV-infected women in South Africa (18-25 years), all study 
participants remained seropositive for HPV-16 and -18 at 12 month follow-up [34]. Antibody titres 
were 50% and 70% lower at 7 and 12 months in the HIV-infected group compared to the HIV-
uninfected group [30,34]. However, HPV-16 and HPV-18 geometric mean titres in the HIV-infected 
group remained 26- and 16-fold higher at one year than those reported in healthy women (15-25 
years) who cleared a natural infection. The bivalent vaccine was reported to have an acceptable 
safety and reactogenicity profile in HIV-infected young women in this trial.  
While the immunogenicity and safety of HPV-vaccination in HIV-infected children and young women 
has been demonstrated [30,32–34], no long-term follow-up of HIV cohorts receiving HPV-vaccination 
have been reported. Therefore the duration of vaccine-induced immunogenicity and the clinical 
significance of the lower antibody titre in HIV-infected children and young women receiving the bi- or 
quadrivalent HPV-vaccination remain unknown. Tailoring of HPV-vaccination guidelines for HIV-
infected children and young women awaits answers to pertinent questions such as the adequacy of a 
two-dose quadrivalent vaccination schedule, the evaluation of the newly available nano-valent HPV-
vaccine, and the requirement/ timing of a booster dose in this group. 
 
Conclusion 
Many of the cancers occurring in HIV-infected children are linked to immunosuppression and 
oncogenic co-infections. Starting cART before severe immunosuppression develops and vaccination 
against oncogenic viruses appear key to prevent cancer in HIV-infected children. Better data on the 
short and long-term risk of developing cancer and the effects of preventive measures in HIV-infected 
children from regions with high burden of HIV/AIDS are urgently needed. 
 
Key points 
 HIV-infected children are at increased risk of developing cancer due to immunosuppression 
and most cancers are associated with oncogenic co-infections. 
 The majority of HIV-infected children live in Sub-Saharan-Africa, but cancer studies in HIV-
infected children from this region are scarce. 
 Starting combined antiretroviral therapy (cART) before severe immunosuppression develops 
is key to prevent cancer in HIV-infected children but most children in low-income countries 
start cART at severe immunosuppression levels.  
 Vaccination against high risk variants of human papilloma virus may protect again cancer 
later in life, however, tailoring of HPV-vaccination guidelines for HIV-infected children and 
young women awaits answers to determine the best vaccination strategies. 
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Figure 1: UNAIDS estimates for number of children [in thousands] living with HIV stratified by age 
group and region in 2016 
 
 
Latin America and the Caribbean: 7,200 children aged 0-4 years; 11,000 children aged 5-9 years; 
14,000 children aged 10-14 years. Middle East and North Africa: 5,200 children aged 0-4 years; 3,400 
children aged 5-9 years; 2,300 children aged 10-14 years. Estimates for Western, Central and Eastern 
Europe, Central Asia and North America are not available (NA). Source: unpublished UNAIDS 2016 
estimates  
 
  
240
190
62
390
170
71
410
150
60
0
100
200
300
400
500
600
700
800
900
1000
Eastern and
Southern Africa
Western and Central
Africa
Asia and the Pacific Latin America and
the Caribbean
Middle East and
North Africa
Th
o
u
sa
n
d
s
Age 0-4 years Age 5-9 years Age 10-14 years
Figure
Figure 2: Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination 
Antiretroviral Therapy from sub-Saharan Africa, Europe and Asia  
 
 
 
 
 
 
 
 
 
 
 
 
Legend: Kaposi Sarcoma incidence rates per 100,000 person-years with 95% confidence intervals, 
adapted from [15] 
 
Asia-Pacific 
 0 (0-27) 
Southern Africa 
 11 (4-35) 
Eastern Africa 
86 (55-133) 
Europe, sub-Saharan African origin 
 81 (26-252) 
Europe, other 
origin 
 0 (0-50) 
Table 1: Literature review 2011-2016: cancer incidence in HIV-infected children in the era of on Combination Antiretroviral Therapy 
 
Study Countries Calendar 
years 
Children 
included 
Total follow-up time 
[years] 
Cancer cases 
identified 
Incidence rate per  
100,000 person-years 
Simard et al 
2012, AIDS 
Cancer Match 
Study [10] 
USA 
 
1996 – 2007 
 
1,370  17,734 37* Overall: 213 
   KS: 17 
   NHL: 132 
   NADC: 63 
 
 
 
Chen et al 
2015,  
NHIRD [11] 
Taiwan 1998-2009 230 NR 7 Overall: NR 
   KS: 150 
   NHL: 75 
   NADC: NR 
 
Bohlius et al 
2016,  
IeDEA-SA [9] 
South Africa 2005 - 2011 
 
11,707 29,348 Total 71, prevalent 47, 
incident 24** 
Overall: 82 
   KS: 34 
   NHL: 31 
   NADC: 17 
 
 
 
Legend: Cancer incidence rate estimates in HIV-infected children published in the last five years. *included children and adolescents diagnosed with AIDS only; 
**prevalent defined as: before cohort enrolment, incident: after cohort enrolment. NHIRD National Health Insurance Research Database; IeDEA-SA 
International Epidemiological Databases to Evaluate AIDS in Southern Africa; NR not reported. 
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